NASDAQ:SLDB - Solid Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Solid Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.56 -0.04 (-1.11 %) (As of 01/27/2020 02:32 PM ET) Add Compare Today's Range$3.51Now: $3.56▼$3.5650-Day Range$3.59MA: $4.14▼$4.7752-Week Range$2.75Now: $3.56▼$25.86Volume3,769 shsAverage Volume631,968 shsMarket Capitalization$163.72 millionP/E RatioN/ADividend YieldN/ABeta1.39 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLDB Previous Symbol CUSIPN/A CIK1707502 Webhttp://www.solidbio.com/ Phone617-337-4680Debt Debt-to-Equity Ratio0.05 Current Ratio6.78 Quick Ratio6.78Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.53 per share Price / Book1.01Profitability EPS (Most Recent Fiscal Year)($2.25) Net Income$-74,800,000.00 Net MarginsN/A Return on Equity-105.82% Return on Assets-88.93%Miscellaneous Employees111 Outstanding Shares45,990,000Market Cap$163.72 million Next Earnings Date3/11/2020 (Estimated) OptionableOptionable Receive SLDB News and Ratings via Email Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SLDB Rates by TradingView Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions What is Solid Biosciences' stock symbol? Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB." How were Solid Biosciences' earnings last quarter? Solid Biosciences Inc (NASDAQ:SLDB) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.67) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.04. View Solid Biosciences' Earnings History. When is Solid Biosciences' next earnings date? Solid Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Solid Biosciences. What price target have analysts set for SLDB? 8 equities research analysts have issued 1 year price targets for Solid Biosciences' shares. Their forecasts range from $2.00 to $22.00. On average, they anticipate Solid Biosciences' share price to reach $9.86 in the next year. This suggests a possible upside of 176.9% from the stock's current price. View Analyst Price Targets for Solid Biosciences. What is the consensus analysts' recommendation for Solid Biosciences? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 2 sell ratings, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences. Has Solid Biosciences been receiving favorable news coverage? Media coverage about SLDB stock has been trending somewhat negative recently, according to InfoTrie. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Solid Biosciences earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Solid Biosciences. Are investors shorting Solid Biosciences? Solid Biosciences saw a decline in short interest in December. As of December 13th, there was short interest totalling 3,440,000 shares, a decline of 5.2% from the November 28th total of 3,630,000 shares. Based on an average daily trading volume, of 1,190,000 shares, the short-interest ratio is presently 2.9 days. Currently, 11.4% of the shares of the company are sold short. View Solid Biosciences' Current Options Chain. Who are some of Solid Biosciences' key competitors? Some companies that are related to Solid Biosciences include Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Rubius Therapeutics (RUBY), Nantkwest (NK), Avrobio (AVRO), Prevail Therapeutics (PRVL), Replimune Group (REPL), Agenus (AGEN), Precision BioSciences (DTIL), Translate Bio (TBIO), Verona Pharma (TARA), Voyager Therapeutics (VYGR), Aptose Biosciences (APTO), BioCryst Pharmaceuticals (BCRX) and Cabaletta Bio (CABA). What other stocks do shareholders of Solid Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Sarepta Therapeutics (SRPT), Fate Therapeutics (FATE), Exelixis (EXEL), Ocular Therapeutix (OCUL), Selecta Biosciences (SELB), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Immunomedics (IMMU), Inovio Pharmaceuticals (INO) and Iovance Biotherapeutics (IOVA). Who are Solid Biosciences' key executives? Solid Biosciences' management team includes the folowing people: Dr. Andrey Juan Zarur, Co-Founder & Chairman of Directors (Age 48)Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 45)Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 47)Dr. Carl Ashley Morris, Chief Scientific Officer (Age 49)Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48) When did Solid Biosciences IPO? (SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers. How do I buy shares of Solid Biosciences? Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Solid Biosciences' stock price today? One share of SLDB stock can currently be purchased for approximately $3.56. How big of a company is Solid Biosciences? Solid Biosciences has a market capitalization of $163.72 million. The company earns $-74,800,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe.View Additional Information About Solid Biosciences. What is Solid Biosciences' official website? The official website for Solid Biosciences is http://www.solidbio.com/. How can I contact Solid Biosciences? Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680. MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 201 (Vote Outperform)Underperform Votes: 184 (Vote Underperform)Total Votes: 385MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: Compound Annual Growth Rate (CAGR)
